Key findings

  • Minutes to hoursto produce degradation products by ball milling, against stress testing over several days and accelerated studies lasting six months
  • 90% of 122medicines tested by the U.S. Shelf-Life Extension Program up to 2015 met the requirements for a shelf-life extension of 19 to 254 months
  • €200 millionestimated cost to the Italian health system of disposed medicines between December 2020 and July 2021, with 72.4% of these being expired medicines
  • $94saved by the Shelf-Life Extension Program in 2005 in stockpile replacement costs for every dollar spent on stability testing of expired medicines

Abstract

The quality of active pharmaceutical ingredients and finished pharmaceutical products is of utmost importance. Since stability is one of the pillars of quality it must carefully be studied before approval. Stability studies follow a strong regulatory framework, such as those established by the International Council for Harmonisation and take a lot of time. First, stress testing under harsh conditions over several days and accelerated studies over 6 months are performed to generate a likely degradation profile. With this collection of degradants, a stability-indicating chromatographic method, mostly high-performance liquid chromatography, can be developed which is able to quantify the active pharmaceutical ingredients and all degradation products. Afterwards, a long-term study must be carried out to determine the storage conditions and expiry date of a medicinal product. As stability studies do not last longer than five years, the maximum shelf life stated on the packaging is five years at the most. Whilst the current regulatory framework has successfully established high standards for the quality and safety of medicinal products, there is still considerable scope for improvement. This review aims to bridge the gap between established guidelines and new technological advances, and introduces mechanochemistry as a novel, rapid and cost-effective screening alternative to conventional stress tests. Furthermore, this article takes a critical look at the clinical reality of strict expiry dates for medicines. Drawing on real-world data and independent studies, it shows how rigid expiry dates lead to significant wastage of medicines worldwide, placing a financial burden on healthcare systems and causing avoidable ethical conflicts. Overall, this review demonstrates how updating current testing paradigms can safely minimise the waste of resources without ever compromising patient safety or clinical efficacy.

Introduction

The quality of pharmaceuticals is strictly and highly regulated. For approval of medicinal products extensive studies on efficacy, quality, and safety are required by law. In Germany, it is regulated by the Medicinal Products Act (Arzneimittelgesetz)1 and in the United States of America (USA) by the Federal Food, Drug, and Cosmetic Act2. Directive 2001/83/EC was adopted for the central approval procedure of the European Medicines Agency3. Among other regulations, these laws stipulate that the respective pharmacopoeias serve as binding standards for medicinal products, excipients and dosage forms4. According to the World Health Organization (WHO)5 there are some 60 national, regional, sub-regional and international pharmacopoeias worldwide. The most relevant pharmacopoeias include the European Pharmacopoeia6, the United States Pharmacopeia7 and the Japanese Pharmacopoeia8. For countries that may not have sufficient resources to establish national pharmacopoeias, the WHO publishes the International Pharmacopoeia9. These all include general analytical testing methods and quality requirements for finished pharmaceutical products (FPPs), monographs on active pharmaceutical ingredients (APIs) and excipients. They describe tests for identity and purity, limits for related substances, residual solvents and heavy metals, as well as specifications for content determination6–9.

Good Manufacturing Practice (GMP) systems are an additional central element, ensuring that medicinal products are manufactured and tested under controlled and reproducible conditions. GMP guidelines for various target markets are regulated by the relevant regulatory authorities, including the GMP of the European Commission for the European Union (EU)10 and the current GMP of the U.S. Food and Drug Administration for the USA11. In low- and middle-income countries, the WHO GMP guidelines12 are commonly applied. In order to harmonise the various national requirements, authorities of EU, USA and Japan founded the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 199013. It is an “[u]nique harmonisation initiative, bringing regulators and the pharmaceutical industry together to discuss the scientific and technical aspects of pharmaceuticals and develop standardized technical guidelines […]”13(p3). Since then, 77 technical guidelines were developed as a tool for the development and manufacture of medical products, which are intended to prevent unnecessary duplication of studies and are implemented by the regulatory authorities. These guidelines cover topics related to efficacy, safety and quality, as well as cross-cutting topics (multidisciplinary guidelines)13.

The scope of this review is to shed a critical and comprehensive light on the regulatory background of stability, the testing concepts and the length of shelf life. Therefore, we have defined the quality of a drug, chemical and physical instabilities, the regulatory background and described stability-indicating analytical methods. Mechanochemistry is introduced as an alternative method. The outcome of stability testing are storage conditions and shelf life which are critically discussed.

Quality of pharmaceuticals

High standards are set for the quality of medicinal products. Quality assurance processes extend from development, through manufacturing and distribution, to end-user application. The quality of the medicinal product must be guaranteed until the end of its shelf life. This is largely dependent on the stability of the respective substance and formulation. A key quality attribute of medicinal products is their API content, which is specified in the applicable pharmacopoeial monograph, ranging typically between 90 and 110%7. Certain changes may reduce the API content and therefore the efficacy and safety.

Chemical and physical instabilities

During storage, various changes can occur in drug substances and products. These include chemical, physical and (micro-) biological changes14.

Various chemical reactions may take place, causing a reduction in the API content and, in the worst case, leading to the formation of harmful or toxic degradation products.

Hydrolysis is the most important chemical degradation reaction involving the cleavage of chemical bonds, e.g. of esters and amides, through reaction with water incorporated into the reaction products. Oxidation is a further significant degradation reaction, i.e. free-radical reactions, including autoxidation, photolysis and chain reactions14,15. In the case of chiral compounds, a change in conformation may occur and can lead to racemization. Isomers such as enantiomers partly have significantly different affinities for enzymes and receptors and therefore differ in terms of efficacy and toxicity16. Alterations of ring systems, including ring closure, ring opening, ring contraction and ring expansion, are also pharmaceutically relevant degradation reactions. The most significant physical change in APIs is the occurrence of various polymorphic forms, which often differ markedly in their solubility behaviour14.

The majority of physical instabilities are observed in FFPs and are related to galenic aspects. Of particular relevance is the mechanical strength of tablets, which can change as a result of moisture absorption or loss. This affects both the disintegration time and the dissolution of the API. Emulsions are at risk of changing the degree of dispersion of the internal phase, which can lead to phase separation. In solutions, the API can precipitate and in suspensions, clumping of the sediment, which inhibits the complete resuspension of the API (caking), may occur and thus lead to incorrect dosing14.

Various parameters and influencing factors can reduce stability. According to the Arrhenius equation, temperature accelerates chemical reactions, including degradation reactions, and also promotes microbial growth. Furthermore, there are groups of substances that are inherently temperature-sensitive, such as biologics, proteins and peptides, which can denature at elevated temperatures. Humidity also stimulates chemical degradation reactions and microbiological growth. Furthermore, it can promote physical changes such as galenic properties, including viscosity, disintegration time and dissolution. The pH value influences the solubility of substances and can promote degradation reactions17. For APIs optimal pH values are determined to balance maximum efficacy with minimal loss of stability18. Exposure to light and oxygen particularly promotes oxidation reactions17.

To ensure the greatest possible stability, these influencing factors should be minimised. Packaging plays a crucial role in this regard, acting as a physical barrier. E.g. for tablets, the primary packaging of choice is a blister pack made of thermoformed plastic and an aluminium cover foil. Each tablet is thus protected from humidity, light, oxygen and microorganisms19. The pH value can be maintained within the appropriate range by adding buffers. The addition of preservatives reduces microbial growth and is particularly recommended in liquid and semi-solid dosage forms. In suspensions, viscosity-increasing agents can slow down sedimentation and caking17.

Stability-indicating analytical methods

Stability-indicating analytical methods must be able to determine changes in a product’s relevant quality characteristics during storage. Chromatographic methods are regarded as the gold standard for determining the stability of medicinal products, as they can simultaneously detect the API and other substances, such as degradation products both qualitatively and quantitatively. Mostly used methods are high-performance liquid chromatography, the first choice of analytical technique, as it is almost universally applicable and offers a high degree of precision; in rare cases gas chromatography, thin-layer chromatography, and capillary electrophoresis are applied20.

Validation of an analytical method provides evidence that the method applied is suitable for its intended purpose. Requirements for validation are described in the ICH Guideline Q2(R2) on the validation of analytical procedures21. The scope of validation tests depends on whether the method developed is intended to determine identity, purity or content. The following parameters are evaluated during method validation:

Specificity is the ability to unequivocally assess the analyte in the presence of other components, and selectivity the ability to ensure that other substances do not interfere with its determination. The range of analyte concentrations within which the analytical method provides results with the required accuracy and precision. For an API, this involves considering the range between the lowest and highest expected concentrations and, in general, linear relationship between analyte concentration and detector response. For impurities that are present at low levels, the detection limit and quantification limit are of particular relevance; for details see ICH Guideline Q2(R2)21.

Regulatory framework of stability studies

ICH Guideline Q1A(R2)22 describes stability testing of new APIs and FPPs and is one of the most important sources of guidance for determining the shelf life of medicinal products and their storage conditions14.

Stress studies, or forced degradation studies, can be useful for new APIs and for the development of analytical methods to assess stability. In these studies, a single batch is tested under harsh conditions (addition of acids, bases and oxidising agents, respectively; light exposure; high temperatures) over a period of several days. Furthermore, these studies provide insight into factors that have a negative impact on the respective substance or preparation. Based on this, a suitable container-closure system (CCS) can be selected22.

Further testing conditions vary depending on the climatic conditions of the country in which the medicinal product is intended to be marketed. For this purpose, the world is divided into four climatic zones (Table 1)23.

Table 1. Four climatic zones with definition and storage conditions adapted from Grimm.23 RH: relative humidity

Climatic ZoneClimate definitionStorage ConditionRepresentative region
ITemperate21 °C/45% RHEU, Japan, USA
IISubtropical and Mediterranean25 °C/60% RH
IIIHot, dry30 °C/35% RHAfrica, Asia, South America, Oceania
IVHot, humid30 °C/70% RH

Stability studies of drug substances and products are performed in suitable CCSs. For drug substances they must simulate at least the CCS for transport and storage, e.g. a lined cardboard drum or a glass bottle. For drug products, they must correspond to the CCS approved for marketing authorisation. This is necessary to assess the potential impact of the packaging material on the product. Substances from the packaging can migrate into the medicinal product, e.g. adhesive components from a label applied to a plastic bottle may migrate into the solution contained therein. Conversely, the API can adsorb onto the packaging, thereby changing the API content14.

Stability studies under specified temperatures and relative humidity (RH) levels, applying specialised GMP-compliant climate chambers equipped with monitoring and recording systems. Whilst, in the event of a prolonged failure, stability studies conducted at temperatures above 25°C do not generally result in any significant damage and storage can be extended by the duration of the outage, samples stored below 8°C can be irreversibly damaged during a failure of the fridge or freezer and must be discarded14.

Three types of stability studies can be distinguished: accelerated, intermediate, and long-term22.

Accelerated studies should run for at least 6 months, with testing performed at a minimum of three time points (e.g. 0, 3, and 6 months). Elevated temperatures and humidity conditions during these studies increase the rate of chemical degradation. For drug substances, these studies help identify potential degradation products and pathways and enable the development and validation of analytical methods for stability testing. Drug products are tested on the basis of the results obtained from the substances22. “Data from these studies, in addition to long-term stability studies, can be used to assess longer term chemical effects at non-accelerated conditions and to evaluate the effect of short-term excursions outside the label storage conditions such as might occur during shipping”22(p13). Intermediate studies are required if significant changes to the substance or product are observed during the accelerated studies. A minimum period of 12 months is recommended, with four testing time points (e.g. 0, 6, 9 and 12 months). Additional studies on the reconstituted or diluted drug product should be conducted to define the in-use period22.

The conditions of long-term studies, with 25°C ± 2°C/60% RH ± 5% RH, based on the mean kinetic temperature of climatic zone I/II, which considers annual temperature variations with lower and higher temperatures in winter and summer, respectively24. Long-term studies should be run for at least 12 months, with testing at three-monthly intervals in the first year, six-monthly intervals in the second year, and annually thereafter until the end of the proposed shelf life22.

Mechanochemistry, alternative stability studies

As described above, regulatory stability studies required to demonstrate the stability of APIs and FPPs are time-consuming, with stress testing over several days and accelerated stability studies at 40 °C lasting six months. Since stability studies have to be provided upon licensing of a drug an acceleration of the processes is welcome.

Most of the studies are performed in solutions. A drug can be formulated as an ointment, emulsion, suppository, and aqueous solution. In these cases, the aforementioned methods are of good predictive power with regard to stability. APIs are mostly formulated as a tablet or coated tablet. Hence, degradation reactions of the API take place solvent-free. Therefore, a solid-state method might be more appropriate for predictive degradation studies and mechanochemistry is a straightforward method for this purpose.

Mechanochemistry has recently become rather popular, mainly in synthesis of simply organic compound and drugs25,26. This is due to the fast progress of reaction and no additional heating and often no catalyst is necessary. Since it is driven by mechanical forces grinding, milling and shearing are required for introduction of high energy. Therefore, high-energy ball mills are used. The milling jars and ball are typically composed of zirconia dioxide (stabilized with Yttria).

Besides the applications in synthesis, a couple of publications describe degradation of compounds by ball milling, e.g. for lignin or perfluorinated alkyl substances, the so-called long-living per- and polyfluoroalkyl substances27–29. Consequently, it is worth to systematically study whether mechanochemical experiments have a predictive power for the degradation of drugs. As early as 2012, Andini et al.30 investigated the degradation of ibuprofen by prolonged milling for 10 and 40 h. They observed a kind of degradation of the acetic acid function on the one hand and an oxidation of isobutyl group on the other hand. In 2018, Buschmann and Handler31 have filed a patent describing a concept of forced degradation by solvent-free ball milling for clopidogrel.

Since clopidogrel is a well-established antiplatelet medicine, used for treatment of heart attacks and strokes32, it is fully characterized with regard to quality assurance. By means of forced degradation studies in solution and solid-state, all degradation products are known33,34. Hence, the degradation products produced by ball milling can be compared with the already known products in order to ensure the validity and reproducibility of the mechanochemical experiments. Interestingly, the international pharmacopoeias6,7 do not report oxidative degradation products as potential degradation products.

In an in-depth study the group of Bolm, Holzgrabe, Beweries and Buschmann35–37 looked into the entire degradation profile by applying various oxidative conditions (potassium permanganate, potassium nitrate and Oxone®) to the APIs and FPPs of clopidogrel and ticlopidine. For the API clopidogrel they found hydroxylation of the N-heterocycle as the most prominent oxidation product, beside the formation of an endo-iminium compound; Oxone® gave the most selective degradation profile, which is similar to previous studies35,36. For ticlopidine and prasugrel, similar degradation products were found in solution and solid-state in addition to chlorinated products, where the chlorination is a result from the reaction with the counterion37. By the way, similar results were obtained when FPPs were investigated although they contain a lot of excipients.

Even though the chemical details are not given here, it becomes quite clear that these studies are a first proof-of-concept. However, it is necessary to proof whether the concept works for other drug substances. Hence a systematic study was performed for five antihypertensive sartans, i.e. losartan, irbesartan, valsartan, olmesartan and telmisartan38. Ball milling by means of the aforementioned oxidative conditions revealed a diverse degradation profile of known and previously not known products. However, in all cases the conversion of the tetrazolyl substituent to a nitrile group and in the case of losartan and irbesartan to a formyl group was observed. Chlorination occurred here as well. Worth mentioning is the fact that the amount of oxidation agents is less important than the time of milling. Again, ball milling was predictive on the one hand and gave new ideas of possible degradation reactions on the other hand. More details on these studies are summarized in Holzgrabe et al.39

Interestingly, ball milling was originally not applied for the prediction of possible degradation products of an API, but for the complete destruction of a substance. E.g. Liu et al.40 completely degrade sulfamethoxazole tablets by means of Feo-activated persulfate-assisted mechanochemical procedure.

Ball milling can result in autoxidation as demonstrated by Iyer et al.41 who studied amorphous mifepristone and olanzapine, respectively, in a polyvinylpyrrolidone vinyl acetate matrix. Both APIs show a 5% degradation, and the autooxidation mechanism was confirmed by comparison with the classical experiment using azo-bis(isobutyronitrile). Diclofenac and caffeine could be mechanochemically degraded by application of SiO2, aluminum, Al2O and Al-Al2O342.

Stereochemistry can also be influenced by mechanochemistry. E.g. prolonged ball milling of dexibuprofen (S-ibuprofen) under basic conditions result in isomerization to give R-ibuprofen43. Poljanić et al.44 observed a racemization of biaryl atropisomers upon ball milling; however, the isomerization was a non-wanted effect of a mechanochemical synthesis pathway.

The elucidation of the degradation products by high-performance liquid chromatography needs a high-resolution mass detection with e.g. a triple quad, time-of-flight or quadrupole time-of-flight (qTOF) mass spectrometer, being a hybrid mass spectrometer. All of them are able to provide a mass-to-charge ratio with four to five exact decimal places. Hence, a detection, quantification and structure elucidation are possible, the latter e.g. by using a qTOF and the fragmentation of ions formed in the mass spectrometer. Backer et al.45,46 have demonstrated the applicability of qTOF for such purposes for the API losartan and its tablets. The same technique was applied for the investigations of ball milling of antiplatelet drugs and sartans described above.

Taking together all examples described here, the production of degradation products took only minutes to hours. The fact, that many degradation products found by ball milling were already described, supports the validity of the approach. Hence, the time saving is enormous.

Shelf life and storage conditions

The stability studies described are intended to demonstrate that the medicinal product is safe throughout its period of use. ICH Guideline Q1E47 describes the evaluation of stability data generated in accordance with ICH Guideline Q1A22 and how the retest period and shelf life of APIs and FPPs are determined.

Shelf life is defined as “[t]he time period during which a drug product is expected to remain within the approved shelf-life specification, provided that it is stored under the conditions defined on the container label“22(p16). These specifications include, amongst other items, “[…] a list of tests, references to analytical procedures and appropriate acceptance criteria […]”48(p1). The tests are designed to assess chemical, physical, biological and microbiological attributes. These include general tests such as qualitative description, tests for the identity of the API, stability-indicating assays, and tests for organic and inorganic impurities and residual solvents. In addition, further tests are conducted depending on the respective dosage form, e.g. for solid drug products such as tablets or hard capsules the following tests are specified: dissolution, disintegration, hardness and friability, uniformity of dosage units, water content and microbial limits48. The expiry date is determined for each batch based on its shelf life.

In the EU, the outer packaging of medicinal products must display certain information, including the expiry date and storage conditions. Based on the available stability data, products are assigned to one of five storage conditions: no special storage conditions, store below 30°C, store below 25°C, store in a refrigerator, or store in a freezer24. Appropriate storage conditions must be maintained at every stage of the supply chain, from the manufacturer through wholesalers, pharmacies, and hospitals to the end user. For EU Member States, harmonised requirements for the distribution of medicinal products have been established in the EU Guidelines on Good Distribution Practice49.

What happens after shelf life?

The supply of medicinal products after their expiry date is prohibited1. The producer of the medicine guarantees its quality only till the end of the shelf life and does not take any responsibility for a drug after its expiry date. Hence, drugs after shelf life are kind of waste, which must be removed from the supply chain and destroyed. However, a large number of pharmaceuticals are exceptionally stable, particularly when stored in accordance with the prescribed conditions50–59. As mentioned earlier, the content is regarded as the leading stability indicator and should not fall below 90%7.

Many studies focus on medicines commonly found in (military) emergency stockpiles. The Shelf-Life Extension Program (SLEP)53, established by the U.S. Department of Defense and the U.S. Food and Drug Administration, systematically tested pharmaceuticals shortly before their expiry date and demonstrated that the shelf life of many products could be extended. 90% of the 122 medicines tested up to 2015 met the requirements for a shelf-life extension of 19 to 254 months. Examples include opioid analgesics such as morphine (32-89 months) and fentanyl (84 months), and antibiotics, e.g. amoxicillin (23 months), ampicillin (49-57 months) and doxycycline (27-50 months) in the form of powder, tablets, capsules or injection solutions. Epinephrine is another important emergency medication used in the treatment of cardiac arrest and anaphylactic shock32 and has been frequently investigated in studies. For 17 out of 33 epinephrine injection solutions, SLEP extended the expiry date by an average of 22 months54. Weir et al.55 examined six parenteral solutions 30 months after their expiry date and reported no changes in API content or microbiological quality. The high stability of epinephrine was also demonstrated by Zilker et al.56, who analysed an 83-year-old ampoule and found a residual API content of 70.4%. Atropine is used as an antidote for organophosphate poisoning and is therefore an essential medicine in military emergency stockpiles32. SLEP extended the shelf life of 495 out of 687 atropine auto-injectors tested by an average of 57 months, and that of 24 out of 27 atropine injection solutions tested by 101 months53. An atropine solution expired 12 years prior still contained 99.5% of the declared concentration, an auto-injector dating from the World War II era contained 74%57. A systematic study on tropane alkaloid ampoules of various manufacturers, which were produced some 70 years ago, demonstrated the high stability of atropine in contrast to the instability of scopolamine with a degradation of more than 30%58.

These are only a few examples of pharmaceuticals whose stability suggests a shelf life considerably longer than the labeled expiry date. Nyondo et al.59 as well as Zilker et al.50 provided a large collection of medicines after expiry and stability outcomes.

The coronavirus disease 2019 (COVID-19) pandemic is a current example, that has attracted strong criticism. Paxlovid, a co-package of two tablets containing ritonavir and nirmatrelvir, respectively, was approved by Pfizer in 2022 for the treatment of COVID-19 infections. Whilst the stability of ritonavir was already known, the lack of stability studies for nirmatrelvir, led to the shelf life was set at one year, with the prospect of adjusting the expiry date based on continuous stability monitoring. Until July 2023, the shelf life has been extended to a total of 24 months for packs with expiry dates between 11/2022 and 12/2023. These packs were therefore still permitted to be dispensed. Package expiry dates set for 01/2024 were not permitted to be extended, as the manufacturer's specifications stipulated that the extended shelf life had already been taken into account for the respective batch. Although independent real-world data showed no significant degradation of the API nirmatrelvir years after the Pfizer set expiry date, the shelf life was not extended further. This decision was taken in the period following the announcement of a substantial price increase. On a global scale, millions of packs of Paxlovid were discarded without any scientific evidence. It is suspected that Pfizer did not carry out any follow-up stability studies with the aim of preventing packs nearing their expiry date from remaining in the market and of selling the drug at the new, significantly higher price60.

Conclusions

The highly regulated investigation of stability of new drugs is laborious, lengthy, and costs a lot of money. Hence, new methods for the stability prediction of APIs and tablets, such as mechanochemistry, are very welcome. Long-term stability studies last at most five years before licensing resulting in a shelf life of five years although the stability of the majority of drugs is far longer. Why not testing the drugs after approval for a longer time? Most likely for most of the drugs the shelf life could be significantly extended which would save a lot of money. E.g. a study estimated the cost to the Italian health system of disposed medicines between December 2020 and July 2021, with 72.4% of these being expired medicines, at €200 million61. In 2005, SLEP saved $94 in stockpile replacement costs for every dollar spent on stability testing of expired medicines52. Furthermore, expired medicines can have a significant impact on the ecosystem, depending on method of disposal62.

It has to be noted: as long as we do not have stability data beyond shelf life, it is not recommended that patients and healthcare providers use the expired medicines! It is up to the regulatory authorities to change the stability regulations. However, the Marketing Authorisation Holders will not be in favour of a prolongation of the shelf life due to the decrease of their profit.

Declarations

Conflicts of interest
The author have no conflicts of interest to declare.
Funding
None.
Acknowledgements
Financial support by the Leibniz-Gemeinschaft for the mechanochemistry by means of the project PHARMSAF (K136/2018) is gratefully acknowledged by C. Bolm, U. Holzgrabe, T. Beweries, and H. Buschmann.

References

  1. Arzneimittelgesetz. Gesetze-im-internet.de. Published August 24, 1976. Updated May 12, 2026. Accessed August 15, 2026. https://www.gesetze-im-internet.de/amg_1976/.
  2. Federal Food, Drug, and Cosmetic Act. Govinfo.gov. Published June 25, 1938. Updated August 7, 2026. Accessed August 15, 2026. https://www.govinfo.gov/content/pkg/COMPS-973/pdf/COMPS-973.pdf.
  3. Directive 2001/83/EC on the Community code relating to medicinal products for human use. Eur.-lex.europa.eu. Published November 6, 2001. Updated January 1, 2025. Accessed August 15, 2026. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02001L0083-20250101.
  4. Yapar EA, Özdemi̇rhan ME. An overview on Pharmacopoeias in the world and monograph elaboration techniques. Univ J Pharm Res 2020;5:57-64. doi:10.22270/ujpr.v5i3.418.
  5. World Health Organization. Index of world pharmacopoeias and pharmacopoeial authorities, Working Document QAS/11.453/Rev.18. Who.int. Published May 2025. Accessed August 15, 2026. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/current-projects/index-of-pharmacopoeias_may_2025.pdf.
  6. Council of Europe. European Pharmacopoeia. 11th ed. Council of Europe; 2022.
  7. United States Pharmacopeial Convention. USP–NF Online. United States Pharmacopeial Convention; 2026. Accessed March 11, 2026. https://www.uspnf.com.
  8. Pharmaceutical and Medical Device Regulatory Science Society of Japan. The Japanese Pharmacopoeia. 18th ed. Yakuji Nippo-sha; 2022.
  9. World Health Organization. The International Pharmacopoeia. 13th ed. Digicollections.net. Published 2025. Accessed August 15, 2026. https://digicollections.net/phint/202502/index.html#p/home.
  10. European Commission. EudraLex, Volume 4, Good Manufacturing Practice (GMP) guidelines. Europa.eu. Published 2025. Accessed August 15, 2026. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  11. U.S. Food and Drug Administration. Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 211. Ecfr.gov. Published December 18, 2025. Accessed August 15, 2026. https://www.ecfr.gov/on/2025-12-18/title-21/chapter-I/subchapter-C/part-211.
  12. Chejor P, Dorji T, Dema N, Stafford A. Good manufacturing practice in low‐ and middle‐income countries: challenges and solutions for compliance. Public Health Chall. 2024;3(1):158. doi:10.1002/puh2.158.
  13. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The International Council for Harmonisation (ICH): An Overview. Ich.org. Published November 2025. Accessed August 15, 2026. https://admin.ich.org/sites/default/files/2025-12/OverviewOfICH_2025_1126_1.pdf.
  14. Grimm W, Harnischfeger G, Tegtmeier M. Stabilitätsprüfung in der Pharmazie: Theorie und Praxis. 3rd ed. ECV Editio Cantor; 2011.
  15. Hovorka SW, Schöneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci. 2001;90(3):253–269. doi:10.7399/fh.10932.
  16. Wünsch B. Die bessere Hälfte bewährter Arzneistoffe. Pharm Ztg. 2005;(30). Accessed August 15, 2026. https://www.pharmazeutische-zeitung.de/titel-30-2005/
  17. Tayade B, Gharge V, Jadhav B, Patil A, Parde C, Patil S. Critical parameters affecting stability of APIs and drug products: a review. Asian J Pharm Anal. 2026;16(1):41. doi:10.52711/2231-5675.2026.00007.
  18. Vázquez-Blanco S, González-Freire L, Dávila-Pousa MC, Crespo-Diz C. pH determination as a quality standard for the elaboration of oral liquid compounding formula. Farm Hosp. 2018;42(6):221–227. doi:10.7399/fh.10932.
  19. Bennett MM. Pharmaceutical packaging and stability studies. IJPIS. 2024;1(6):103–118. doi:10.54660/IJPIS.2024.1.6.103-118.
  20. Chew YL, Khor MA, Lim YY. Choices of chromatographic methods as stability indicating assays for pharmaceutical products: a review. Heliyon. 2021;7(3):e06553. doi:10.1016/j.heliyon.2021.e06553.
  21. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline: validation of analytical procedures Q2(R2). Ich.org. Published November 1, 2023. Updated April 4, 2025. Accessed August 15, 2026. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130_ErrorCorrection_2025.pdf.
  22. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: stability testing of new drug substances and products Q1A(R2). Ich.org. Published February 6, 2003. Accessed August 15, 2026. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.
  23. Grimm W. Extension of the international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev Ind Pharm. 1998;24:313–325. doi:10.3109/03639049809085626.
  24. European Medicines Agency. Guideline on declaration of storage conditions. Document CPMP/QWP/609/96/Rev 2. Ema.europa.eu. Published January 1998. Updated November 19, 2007. Accessed August 15, 2026. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-storage-conditions_en.pdf.
  25. Friščić T, Mottillo C, Titi HM. Mechanochemistry for synthesis. Angew Chem Int Ed. 2020;132:1030-1041. doi:10.1002/ange.201906755.
  26. Breinsperger J, Podlesnik N, Mele F, Schnürch M. Silent partners in the mill: unveiling the role of additives in mechanochemical synthesis. Chem Eur J. 2026;32(9):e03536. doi:10.1002/chem.202503536.
  27. Gobindlal K, Zujovic Z, Jaine J, Weber CC, Sperry J. Solvent-free, ambient temperature and pressure destruction of perfluorosulfonic acids under mechanochemical conditions: degradation intermediates and fluorine fate. Environ Sci Technol. 2023;57(1):277-285. doi:10.1021/acs.est.2c06673.
  28. Gobindlal K, Shields E, Whitehill A, Weber CC, Sperry J. Mechanochemical destruction of per- and polyfluoroalkyl substances in aqueous film-forming foams and contaminated soil. Environ Sci Adv. 2023; 2(7):982-989. doi:10.1039/d3va00099k.
  29. Ateia M, Skala LP, Yang A, Dichtel WR. Product analysis and insight into the mechanochemical destruction of anionic PFAS with potassium hydroxide. J Hazard Mater Adv. 2021;3:100014. doi:10.1016/j.hazadv.2021.100014.
  30. Andini S, Bolognese A, Formisano D, Manfra M, Montagnaro F, Santoro L. Mechanochemistry of ibuprofen pharmaceutical. Chemosphere. 2012;88(5):548-553. doi:10.1016/j.chemosphere.2012.03.025.
  31. Buschmann HH, Handler NC, inventors. Mechanochemical process in a solid-state reaction. US patent 12,186,740 B2. Published 2018.
  32. Geisslinger G, Gudermann T, Hinz B, et al. Mutschler Arzneimittelwirkungen: Pharmakologie, Klinische Pharmakologie, Toxikologie. 12th ed. Wissenschaftliche Verlagsgesellschaft; 2025.
  33. Deshmukh PR, Gaikwad VL, Tamane PK, Mahadik KR, Purohit RN. Development of stability-indicating HPLC method and accelerated stability studies for osmotic and pulsatile tablet formulations of clopidogrel bisulfate. J Pharm Biomed Anal. 2019;165:346–356. doi:10.1016/j.jpba.2018.12.020.
  34. Raijada DK, Prasad B, Paudel A, Shah RP, Singh S. Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulfate under solid-state conditions. J Pharm Biomed Anal. 2010;52(3):332-344. doi:10.1016/j.jpba.2009.05.001.
  35. Kaiser RP, Krake EF, Backer L, et al. Ball milling - a new concept for predicting degradation profiles in active pharmaceutical ingredients. Chem Commun. 2021;57(90):11956-11959. doi:10.1039/d1cc04716g.
  36. Krake EF, Baumann W. Selective oxidation of clopidogrel by peroxymonosulfate (PMS) and sodium halide (NaX) system: an NMR study. Molecules. 2021;26(19):5921. doi:10.3390/molecules26195921.
  37. Krake EF, Backer L, Andres B, et al. Mechanochemical oxidative degradation of thienopyridine containing drugs: toward a simple tool for the prediction of drug stability. ACS Cent Sci. 2023;9(6):1150–1159. doi:10.1021/acscentsci.3c00167.
  38. Amer MM, Backer L, Buschmann H, et al. Prediction of degradation profiles for various sartans under solvent-free mechanochemical conditions. Anal Chem. 2024;96(32):13166-13173. doi:10.1021/acs.analchem.4c02025.
  39. Holzgrabe U, Buschmann H, Handler N, et al. Mechanochemical degradation of active pharmaceutical ingredients (APIs): a simple tool for the prediction of drug stability. Chimia. 2025;79(9):614–621. doi:10.2533/chimia.2025.614.
  40. Liu X, Zhang X, Shao K, et al. Fe0 -activated persulfate-assisted mechanochemical destruction of expired compound sulfamethoxazole tablets. RSC Adv. 2016;6(25):20938–20948. doi:10.1039/c5ra27113d.
  41. Iyer J, Barbosa M, Saraf I, Pinto JF, Paudel A. Mechanoactivation as a tool to assess the autoxidation propensity of amorphous drugs. Mol Pharm. 2023;20(2):1112–1128. doi:10.1021/acs.molpharmaceut.2c00841.
  42. Correa-Navarro YM, López GD, Carazzone C, Giraldo L, Moreno-Piraján JC. Mechanochemical degradation of caffeine and diclofenac using biochar of fique bagasse in the presence of Al: monitoring by mass spectrometry. ACS Omega. 2023;8(42):38905–38915. doi:10.1021/acsomega.3c03051.
  43. Urlaub J, Kaiser RP, Scherf‐Clavel O, Bolm C, Holzgrabe U. Investigation of isomerization of dexibuprofen in a ball mill using chiral capillary electrophoresis. Electrophoresis. 2021;42(17-18):1790–1799. doi:10.1002/elps.202000307.
  44. Poljanić L, Leyssens T, Collard L, Baier DM. When chirality breaks: mechanochemical degradation of biaryl atropisomers. RSC Mechanochem. 2026;3(2):218–223. doi:10.1039/d5mr00132c.
  45. Backer L, Buschmann H, Kinzig M, Sörgel F, Scherf-Clavel O, Holzgrabe U. Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities. J Pharm Biomed Anal. 2024;240:115955. doi:10.1016/j.jpba.2023.115955.
  46. Backer L, Kinzig M, Sörgel F, Scherf-Clavel O, Holzgrabe U. Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry. J Pharm Biomed Anal. 2024;245:116160. doi:10.1016/j.jpba.2024.116160.
  47. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Q1E: evaluation of stability data. Ich.org. Published February 6, 2002. Updated February 6, 2003. Accessed August 15, 2026. https://database.ich.org/sites/default/files/Q1E_Guideline.pdf.
  48. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Q6A: specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Ich.org. Published July 8, 1997. Updated October 6, 1999. Accessed August 15, 2026. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf.
  49. European Commission. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use. Eur-lex.eu. Published November 5, 2013. Accessed August 15, 2026. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013XC1123(01).
  50. Zilker M, Sörgel F, Holzgrabe U. A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates. J Pharm Biomed Anal. 2019;166:222–235. doi:10.1016/j.jpba.2019.01.016.
  51. Cantrell L, Suchard JR, Wu A, et al. Stability of active ingredients in long-expired prescription medications. Arch Intern Med. 2012;172(21):1685-1687. doi:10.1001/archinternmed.2012.4501.
  52. Courtney B, Easton J, Inglesby TV, SooHoo C. Maximizing state and local medical countermeasure stockpile investments through the Shelf-Life Extension Program. Biosecur Bioterror. 2009;7(1):101–107. doi:10.1089/bsp.2009.0011.
  53. Diven DG, Bartenstein DW, Carroll DR. Extending shelf life just makes sense. Mayo Clin Proc. 2015; 90(11):1471–1474. doi:10.1016/j.mayocp.2015.08.007.
  54. Lyon RC, Taylor JS, Porter DA, Prasanna HR, Hussain AS. Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci. 2006;95(7):1549–1560. doi:10.1002/jps.20636.
  55. Weir WB, Fred LY, Pike M, et al. Expired epinephrine maintains chemical concentration and sterility. Prehosp Emerg Care. 2018;22(4):414–418. doi:10.1080/10903127.2017.1402109.
  56. Zilker M, Sörgel F, Holzgrabe U. A stability-study of expired ampoules manufactured more than 40 years ago. J Pharm Biomed Anal. 2018;150: 318–326. doi:10.1016/j.jpba.2017.12.019.
  57. Schier JG, Ravikumar PR, Nelson LS, Heller MB, Howland MA, Hoffman RS. Preparing for chemical terrorism: stability of injectable atropine sulfate. Acad Emerg Med. 2004;11(4):329–334. doi:10.1197/j.aem.2003.06.014.
  58. Klapper S, Holzgrabe U. Stability of expired tropane alkaloid ampoules using HPLC-UV/CAD. J Pharm Biomed Anal. 2026;270:117297. doi:10.1016/j.jpba.2025.117297.
  59. Nyondo GG, Manguzu MA, Kaale EA, Adams E. Stability and efficacy of medicines beyond their expiration dates: a systematic review. Ther Innov Regul Sci. 2026. doi:10.1007/s43441-026-00995-z.
  60. Holzgrabe U, Kinzig M, Sörgel F. Arzneimittelstabilität: Lehren aus dem Paxlovid-Fall. Pharm Ztg. 2025; 170:1198–1204.
  61. Romanelli L, Lucente F. Analysis of medicines returned to pharmacies for disposal and estimation of the cost due to medicine wasting. Explor Res Clin Soc Pharm. 2022;5:100133. doi:10.1016/j.rcsop.2022.100133.
  62. Vishwas DK. Effect of expired pharmaceutical dumping on ecological community. BLDE Univ J Health Sci. 2022;7(2):192–197. doi:10.4103/bjhs.bjhs_8_22.

Article information

Authors

How to cite

Holzgrabe, U., Klapper, S., 2026. Rigid Rules versus Emerging Science for Stability Studies: An Overview of the Regulatory Framework, Mechanochemistry as a Novel Tool, and a Critical Examination of the Shelf Life of Pharmaceutical Products. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0567

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
135

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.